시장보고서
상품코드
1151941

세계의 폐렴 치료제 시장 규모 조사와 예측 : 치료제별, 유통 채널별, 연령층별, 지역별 분석(2022-2029년)

Global Pneumonia Therapeutics Market Size study & Forecast, by Therapeutics, by Distribution Channel, and by Age Group and Regional Analysis, 2022-2029

발행일: | 리서치사: Bizwit Research & Consulting LLP | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 폐렴 치료제 시장은 2021년에 약 132억 4000만 달러로 평가되며, 예측 기간인 2022-2029년에는 8.5%를 넘는 건전한 성장률로 성장할 것으로 예상되고 있습니다.

목차

제1장 주요 요약

  • 시장 스냅숏
  • 세계·부문별 시장 추정·예측, 2019-2029년
    • 폐렴 치료제 시장(지역별) : 2019-2029년
    • 폐렴 치료제 시장(치료제별) : 2019-2029년
    • 폐렴 치료제 시장(유통경로별) : 2019-2029년
    • 폐렴 치료제 시장(연령층별) : 2019-2029년
  • 주요 동향
  • 조사 방법
  • 조사 전제조건

제2장 세계의 폐렴 치료제 시장 정의와 범위

  • 조사의 목적
  • 시장의 정의와 범위
    • 조사 대상 범위
    • 산업의 진화
  • 조사 대상년
  • 통화 환산율

제3장 세계의 폐렴 치료제 시장 역학

  • 폐렴 치료제 시장 영향 분석(2019-2029년)
    • 시장 촉진요인
      • 폐렴 발생 건수의 증가
      • 미충족 요구의 증가
      • 대형 시장 기업의 전략적 구상
    • 시장이 해결해야 할 과제
      • 높은 치료비
      • 예방 백신에 대한 인식 부족
    • 시장 기회
      • 개발도상 지역에서 헬스케어 지출의 증가
      • 의약품 분야에서 연구개발 활동의 활발화

제4장 세계의 폐렴 치료제 시장 산업 분석

  • Porter's 5 Force 모델
    • 공급 기업의 교섭력
    • 구매자의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계
  • Porter's 5 Force 모델에 대한 미래적 어프로치(2019-2029년)
  • PEST 분석
    • 정치적
    • 경제적
    • 사회적
    • 기술적
  • 투자 채택 모델
  • 애널리스트의 결론·제안
  • TOP 투자 기회
  • 주요 성공 전략

제5장 리스크 평가 : COVID-19의 영향

  • COVID-19가 업계에 미치는 전체적인 영향 평가
  • COVID-19 이전과 COVID-19 이후 시장 시나리오

제6장 세계의 폐렴 치료제 시장, 치료제별

  • 시장 스냅숏
  • 세계의 폐렴 치료제 시장 : 치료제별), 실적 - 잠재력 분석
  • 세계의 폐렴 치료제 시장, 치료제별 추정·예측 2019-2029년
  • 폐렴 치료제 시장 : 하위 부문 분석
    • 예방 백신
    • 치료제

제7장 세계의 폐렴 치료제 시장 : 유통 채널별

  • 시장 스냅숏
  • 세계의 폐렴 치료제 시장 : 유통 채널별, 실적 - 잠재력 분석
  • 세계의 폐렴 치료제 시장 : 유통 채널별 추정·예측 2019-2029년
  • 폐렴 치료제 시장 : 하위 부문 분석
    • 병원
    • 의약품 판매점
    • 기타

제8장 세계의 폐렴 치료제 시장 : 연령층별

  • 시장 스냅숏
  • 세계의 폐렴 치료제 시장 : 연령층별), 퍼포먼스 - 잠재력 분석
  • 세계의 폐렴 치료제 시장 : 연령층별 추정·예측(2019-2029년
  • 폐렴 치료제 시장 : 하위 부문 분석
    • 소아용
    • 성인
    • 노년

제9장 세계의 폐렴 치료제 시장 : 지역별 분석

  • 폐렴 치료제 시장, 지역별 시장 스냅숏
  • 북미
    • 미국
      • 치료제별 추정·예측, 2019-2029년
      • 유통 채널별 추정·예측, 2019-2029년
      • 연령층별 추정·예측, 2019-2029년
    • 캐나다
  • 유럽의 폐렴 치료제 시장 스냅숏
    • 영국
    • 독일
    • 프랑스
    • 스페인
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양의 폐렴 치료제 시장 스냅숏
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카의 폐렴 치료제 시장 스냅숏
    • 브라질
    • 멕시코
  • 세계의 기타 지역

제10장 경쟁 정보

  • 주요 시장 전략
  • 기업 개요
    • Abbott Laboratories
      • 주요 정보
      • 개요
      • 재무(데이터 입수가 가능한 경우)
      • 제품 개요
      • 최근 개발 상황
    • Bayer AG
    • Eli Lilly & Company
    • GlaxoSmithKline PLC.
    • Lupin Pharmaceuticals, Inc.
    • Merck KGAA
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Teva Pharmaceuticals Industries Limited.

제11장 조사 프로세스

  • 조사 프로세스
    • 데이터 마이닝
    • 분석
    • 시장 추정
    • 밸리데이션
    • 출판
  • 조사 속성
  • 조사 전제조건
KSA 22.11.24

Global Pneumonia Therapeutics Market is valued approximately USD 13.24 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period 2022-2029. Pneumonia is a type of acute respiratory infection that inflames the air sacs in one or both lungs caused by bacteria, viruses, or fungi. The signs and symptoms of Pneumonia include cough, with greenish, yellow, and bloody mucus, fever, sweating, shortness of breath, rapid, shallow breathing, and stabbing chest pain among others. The increasing incidences of pneumonia and growing unmet clinical needs as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to UNICEF - as of 2019, globally around 700,000 children under five lost their lives every year, accounting for around 2,000 deaths every day. In addition, South Asia (2,500 cases per 100,000 children) is the most affected region followed by West and Central Africa (1,620 cases per 100,000 children). Also, rising healthcare spending in developing regions and growing number of R&D activities in pharmaceuticals sector would create lucrative growth prospectus for the market over the forecast period. However, a high treatment cost and lack of awareness towards preventive vaccines impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pneumonia Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of revenue due to presence of leading pharmaceutical giants as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising geriatric population and increasing prevalence of pneumonia in children in the region.

Major market players included in this report are:

Abbott Laboratories

Bayer AG

Eli Lilly & Company

GlaxoSmithKline PLC.

Lupin Pharmaceuticals, Inc.

Merck KGAA

Novartis AG

Pfizer, Inc.

Sanofi S.A.

Teva Pharmaceuticals Industries Limited.

Recent Developments in the Market:

  • In December 2020, India based Serum Institute of India launched first indigenous vaccine for pneumonia. The new vaccines would be provided for children throughout the world with the help of UNICEF network.
  • In July 2021, US based Merck received the U.S. Food and Drug Administration (FDA) approval for its new VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) intended for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Global Pneumonia Therapeutics Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Therapeutics, Distribution Channel, Age Group, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutics

Prevention Vaccines

Treatment Drugs

By Distribution Channel

Hospitals

Pharmaceutical Stores

Other

By Age Group

Pediatric

Adult

Geriatric

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Pneumonia Therapeutics Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Pneumonia Therapeutics Market, by Therapeutics, 2019-2029 (USD Billion)
    • 1.2.3. Pneumonia Therapeutics Market, by Distribution Channel, 2019-2029 (USD Billion)
    • 1.2.4. Pneumonia Therapeutics Market, by Age Group, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Pneumonia Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Pneumonia Therapeutics Market Dynamics

  • 3.1. Pneumonia Therapeutics Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidences of Pneumonia
      • 3.1.1.2. Growing unmet clinical needs
      • 3.1.1.3. Strategic initiatives from leading market players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High treatment cost.
      • 3.1.2.2. Lack of awareness towards preventive vaccines.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising healthcare spending in developing regions.
      • 3.1.3.2. Growing number of R&D activities in pharmaceuticals sector.

Chapter 4. Global Pneumonia Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Pneumonia Therapeutics Market, by Therapeutics

  • 6.1. Market Snapshot
  • 6.2. Global Pneumonia Therapeutics Market by Therapeutics, Performance - Potential Analysis
  • 6.3. Global Pneumonia Therapeutics Market Estimates & Forecasts by Therapeutics 2019-2029 (USD Billion)
  • 6.4. Pneumonia Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Prevention Vaccines
    • 6.4.2. Treatment Drugs

Chapter 7. Global Pneumonia Therapeutics Market, by Distribution Channel

  • 7.1. Market Snapshot
  • 7.2. Global Pneumonia Therapeutics Market by Distribution Channel, Performance - Potential Analysis
  • 7.3. Global Pneumonia Therapeutics Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 7.4. Pneumonia Therapeutics Market, Sub Segment Analysis
    • 7.4.1. Hospitals
    • 7.4.2. Pharmaceutical Stores
    • 7.4.3. Others

Chapter 8. Global Pneumonia Therapeutics Market, by Age Group

  • 8.1. Market Snapshot
  • 8.2. Global Pneumonia Therapeutics Market by Age Group, Performance - Potential Analysis
  • 8.3. Global Pneumonia Therapeutics Market Estimates & Forecasts by Age Group 2019-2029 (USD Billion)
  • 8.4. Pneumonia Therapeutics Market, Sub Segment Analysis
    • 8.4.1. Pediatric
    • 8.4.2. Adult
    • 8.4.3. Geriatric

Chapter 9. Global Pneumonia Therapeutics Market, Regional Analysis

  • 9.1. Pneumonia Therapeutics Market, Regional Market Snapshot
  • 9.2. North America Pneumonia Therapeutics Market
    • 9.2.1. U.S. Pneumonia Therapeutics Market
      • 9.2.1.1. Therapeutics breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Distribution Channel breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Age Group breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Pneumonia Therapeutics Market
  • 9.3. Europe Pneumonia Therapeutics Market Snapshot
    • 9.3.1. U.K. Pneumonia Therapeutics Market
    • 9.3.2. Germany Pneumonia Therapeutics Market
    • 9.3.3. France Pneumonia Therapeutics Market
    • 9.3.4. Spain Pneumonia Therapeutics Market
    • 9.3.5. Italy Pneumonia Therapeutics Market
    • 9.3.6. Rest of Europe Pneumonia Therapeutics Market
  • 9.4. Asia-Pacific Pneumonia Therapeutics Market Snapshot
    • 9.4.1. China Pneumonia Therapeutics Market
    • 9.4.2. India Pneumonia Therapeutics Market
    • 9.4.3. Japan Pneumonia Therapeutics Market
    • 9.4.4. Australia Pneumonia Therapeutics Market
    • 9.4.5. South Korea Pneumonia Therapeutics Market
    • 9.4.6. Rest of Asia Pacific Pneumonia Therapeutics Market
  • 9.5. Latin America Pneumonia Therapeutics Market Snapshot
    • 9.5.1. Brazil Pneumonia Therapeutics Market
    • 9.5.2. Mexico Pneumonia Therapeutics Market
  • 9.6. Rest of The World Pneumonia Therapeutics Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Abbott Laboratories
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Bayer AG
    • 10.2.3. Eli Lilly & Company
    • 10.2.4. GlaxoSmithKline PLC.
    • 10.2.5. Lupin Pharmaceuticals, Inc.
    • 10.2.6. Merck KGAA
    • 10.2.7. Novartis AG
    • 10.2.8. Pfizer, Inc.
    • 10.2.9. Sanofi S.A.
    • 10.2.10. Teva Pharmaceuticals Industries Limited.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제